Oxytocin vs Carbetocin
Oxytocin and carbetocin are both oxytocin receptor agonists used in obstetrics, but they differ significantly in pharmacokinetics. Oxytocin has a short half-life (3–5 minutes) requiring continuous infusion, while carbetocin has an extended half-life (~40 minutes) allowing single-dose administration.
Structural Differences
Section titled “Structural Differences”Oxytocin
Section titled “Oxytocin”- Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (cyclic)
- Modifications: Disulfide bond (Cys1–Cys6), C-terminal amidation
- MW: 1,007 Da
- Charge at pH 7.4: 0
- Half-life: 3–5 minutes
- Stability: Susceptible to oxytocinase
Carbetocin
Section titled “Carbetocin”- Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (cyclic)
- Modifications: 1-Thia modification (Cys1 → Cys-CH₂-S), C-terminal amidation
- MW: 988 Da
- Charge at pH 7.4: 0
- Half-life: 40–60 minutes
- Stability: Resistant to oxytocinase
Mechanism of Action
Section titled “Mechanism of Action”Shared Mechanism
Section titled “Shared Mechanism”Both agents stimulate uterine contraction through:
- Oxytocin receptor (OXTR) binding on myometrium
- Gαq → PLC → IP₃ + DAG signaling pathway
- IP₃ → Ca²⁺ release from sarcoplasmic reticulum
- Ca²⁺-calmodulin → MLCK activation
- Myosin light chain phosphorylation → contraction
Pharmacokinetic Differences
Section titled “Pharmacokinetic Differences”| Property | Oxytocin | Carbetocin |
|---|---|---|
| Receptor affinity | High (native) | High (native-like) |
| Onset of action | 3–5 minutes | 2–3 minutes |
| Peak uterine contraction | 5–10 minutes | 5–10 minutes |
| Duration of action | 30–60 minutes | 2–4 hours |
| Half-life | 3–5 minutes | 40–60 minutes |
| Dosing | Continuous infusion | Single dose |
Uterine Contraction Effects
Section titled “Uterine Contraction Effects”Oxytocin
Section titled “Oxytocin”- Peak contraction: 5–10 minutes after bolus
- Contraction frequency: 3–5 contractions per 10 minutes
- Contraction amplitude: 60–80 mmHg
- Duration: 30–60 minutes per dose
- Tachyphylaxis: Develops with continuous use
Carbetocin
Section titled “Carbetocin”- Peak contraction: 5–10 minutes after injection
- Contraction frequency: 3–4 contractions per 10 minutes
- Contraction amplitude: 50–70 mmHg
- Duration: 2–4 hours per dose
- Tachyphylaxis: Less than oxytocin
Clinical Applications
Section titled “Clinical Applications”Oxytocin
Section titled “Oxytocin”Primary indications:
- Labor induction: Cervical ripening + labor stimulation
- Labor augmentation: Inadequate uterine contractions
- Postpartum hemorrhage: Active management of third stage
- Incomplete abortion: Uterine evacuation
Dosing protocols:
- Induction: 1–2 mU/min IV, titrate to 20–40 mU/min
- Augmentation: 1–2 mU/min IV, titrate to contractions
- Postpartum: 10–40 U IV after delivery
- Hemorrhage: 10–40 U IV bolus
Carbetocin
Section titled “Carbetocin”Primary indications:
- Postpartum hemorrhage prevention: Single-dose prophylaxis
- Cesarean section: Uterine atony prevention
- Vaginal delivery: Uterine atony prevention
Dosing protocols:
- Cesarean section: 100 µg IV single dose
- Vaginal delivery: 100 µg IM single dose
- Repeat dosing: Not typically required
- High-risk patients: May repeat once after 2 hours
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Oxytocin | Carbetocin |
|---|---|---|
| Half-life | 3–5 min | 40–60 min |
| T_max (uterine) | 5–10 min | 5–10 min |
| Duration of action | 30–60 min | 2–4 hours |
| Bioavailability (IV) | 100% | 100% |
| Bioavailability (IM) | ~50% | ~80% |
| Volume of distribution | ~0.3 L/kg | ~0.2 L/kg |
| Clearance | ~20 mL/min/kg | ~5 mL/min/kg |
| Protein binding | ~30% | ~30% |
Efficacy Comparison
Section titled “Efficacy Comparison”Postpartum Hemorrhage Prevention
Section titled “Postpartum Hemorrhage Prevention”| Parameter | Oxytocin | Carbetocin |
|---|---|---|
| PPH incidence (cesarean) | 10–15% | 6–10% |
| PPH incidence (vaginal) | 5–10% | 3–7% |
| Blood loss reduction | 100–200 mL | 150–250 mL |
| Uterine atony | 5–10% | 2–5% |
| Need for additional uterotonics | 10–15% | 3–7% |
Labor Induction/Augmentation
Section titled “Labor Induction/Augmentation”| Parameter | Oxytocin | Carbetocin |
|---|---|---|
| Success rate | 70–80% | Not indicated |
| Time to delivery | 6–12 hours | Not indicated |
| Cesarean section rate | 15–25% | Not indicated |
| Contraction pattern | Adjustable | Fixed |
Safety Profile
Section titled “Safety Profile”Oxytocin
Section titled “Oxytocin”Common adverse events (>5%):
- Nausea (10–15%)
- Vomiting (5–10%)
- Uterine hyperstimulation (5–10%)
- Water intoxication (rare)
- Fetal distress (5–10%)
Serious adverse events (rare):
- Uterine rupture
- Amniotic fluid embolism
- Hypotension
- Anaphylaxis
- Water intoxication (hyponatremia)
Long-term concerns:
- Neonatal jaundice (controversial)
- Autism spectrum (controversial)
- Maternal water intoxication (high doses)
Carbetocin
Section titled “Carbetocin”Common adverse events (>5%):
- Nausea (10–15%)
- Vomiting (5–10%)
- Abdominal pain (5–10%)
- Dizziness (5–10%)
- Headache (5–10%)
Serious adverse events (rare):
- Uterine hyperstimulation
- Hypertension (transient)
- Myocardial ischemia (rare)
- Anaphylaxis
Long-term concerns:
- Minimal (single dose)
- No water intoxication risk
- No fetal effects (single dose)
Dosing Comparison
Section titled “Dosing Comparison”Oxytocin
Section titled “Oxytocin”- Route: Intravenous (continuous infusion)
- Starting dose: 1–2 mU/min
- Titration: 1–2 mU/min every 20–30 minutes
- Maximum dose: 40 mU/min
- Monitoring: Continuous fetal and uterine monitoring
- Duration: Until delivery (labor) or postpartum (hemorrhage)
Carbetocin
Section titled “Carbetocin”- Route: Intravenous or intramuscular
- Dose: 100 µg single dose
- Timing: Immediately after delivery
- Repeat dosing: May repeat once after 2 hours
- Monitoring: Standard postpartum monitoring
- Duration: Single dose
Formulation and Stability
Section titled “Formulation and Stability”Oxytocin
Section titled “Oxytocin”- Formulation: Injectable solution (10 U/mL, 5 U/mL)
- Storage: 2–8°C (refrigerated)
- Stability: 24 months (unopened)
- Dilution: Dextrose 5% or saline
- Compatibility: Compatible with common IV solutions
Carbetocin
Section titled “Carbetocin”- Formulation: Injectable solution (100 µg/mL)
- Storage: 2–8°C (refrigerated)
- Stability: 24 months (unopened)
- Dilution: Direct injection or dilute in saline
- Compatibility: Compatible with common IV solutions
Cost and Availability
Section titled “Cost and Availability”| Parameter | Oxytocin | Carbetocin |
|---|---|---|
| Cost per dose | $5–15 | $50–100 |
| Cost per treatment | $20–100 | $50–100 |
| Insurance coverage | Broad | Broad |
| Availability | Universal | Limited |
| Generic availability | Yes | Yes |
| Formulation | Multiple | Single |
Clinical Decision Algorithm
Section titled “Clinical Decision Algorithm”When to Choose Oxytocin
Section titled “When to Choose Oxytocin”- Labor induction/augmentation: First-line agent
- Active labor management: Titration needed
- Postpartum hemorrhage: High-dose therapy
- Resource-limited settings: Lower cost
- Continuous monitoring available: Safety monitoring
When to Choose Carbetocin
Section titled “When to Choose Carbetocin”- Postpartum hemorrhage prevention: Single-dose prophylaxis
- Cesarean section: Uterine atony prevention
- High-risk patients: Repeat dosing unlikely
- Limited monitoring: Single dose easier
- Water intoxication risk: No free water
Special Populations
Section titled “Special Populations”Renal Impairment
Section titled “Renal Impairment”- Oxytocin: Dose reduction not required (short half-life)
- Carbetocin: Use with caution (longer half-life)
Hepatic Impairment
Section titled “Hepatic Impairment”- Oxytocin: Minimal hepatic metabolism
- Carbetocin: Minimal hepatic metabolism
Elderly Patients
Section titled “Elderly Patients”- Oxytocin: Use with caution (increased sensitivity)
- Carbetocin: Use with caution (increased sensitivity)
Pediatric Patients
Section titled “Pediatric Patients”- Oxytocin: Not indicated
- Carbetocin: Not indicated
Future Directions
Section titled “Future Directions”- Extended-release oxytocin formulations: Depot formulations
- Oral oxytocin: Oral bioavailability
- Carbetocin combinations: With other uterotonics
- Personalized dosing: Based on patient characteristics
- Long-term safety data: Neonatal outcomes
References
Section titled “References”- World Health Organization. “WHO model list of essential medicines.” WHO 2023.
- Su LL, et al. “Carbetocin for postpartum hemorrhage prevention.” Cochrane Database Syst Rev 2018;4:CD005457.
- Dalili S, et al. “Carbetocin vs oxytocin for postpartum hemorrhage.” J Obstet Gynaecol Res 2016;42:1456-1461.
- Boucher M, et al. “Carbetocin in cesarean section.” Am J Obstet Gynecol 2006;195:1251-1256.
- Hendricks CH, et al. “Oxytocin pharmacokinetics.” Am J Obstet Gynecol 1991;165:1775-1780.